<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Bozas, G.</style></author><author><style face="normal" font="default" size="100%">Antoniou, N.</style></author><author><style face="normal" font="default" size="100%">Poulias, I.</style></author><author><style face="normal" font="default" size="100%">Katsifotis, H.</style></author><author><style face="normal" font="default" size="100%">Skolarikos, A.</style></author><author><style face="normal" font="default" size="100%">Mitropoulos, D.</style></author><author><style face="normal" font="default" size="100%">Alamanis, C.</style></author><author><style face="normal" font="default" size="100%">Alivizatos, G.</style></author><author><style face="normal" font="default" size="100%">Deliveliotis, H.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience</style></title><secondary-title><style face="normal" font="default" size="100%">European Urology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Docetaxel</style></keyword><keyword><style  face="normal" font="default" size="100%">Estramustine</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Prostate cancer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-37349060061&amp;doi=10.1016%2fj.eururo.2007.03.072&amp;partnerID=40&amp;md5=0b26b70bbe8e01760b2562c2ac6feb5a</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">53</style></volume><pages><style face="normal" font="default" size="100%">323 - 332</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Objectives: To investigate potential prognostic and predictive factors in patients with androgen-independent prostate cancer (AIPC) treated with docetaxel chemotherapy. Methods: This analysis included 94 consecutive AIPC patients who were treated between March 2001 and May 2006 with biweekly docetaxel 45 mg/m2 (day 2) and estramustine 140 mg three dimes daily (days 1-3). Results: Prostate-specific antigen (PSA) responses were observed in 45 of 84 evaluable patients (53%), whereas objective responses were observed in 16 of 40 patients with measurable disease (40%). Median survival (OS) was 16.2 mo (95% confidence interval [CI], 12.9-19.4) and median time to PSA progression (TTP) 5.0 mo (95%CI, 3.6-7.1). OS was independently associated with pain score baseline PSA and weight loss. Patients with only extraosseous disease had higher PSA response rate (87% vs. 49%, p = 0.014) and superior TTP compared with patients with bone metastases with or without extraosseous disease (7.3 vs. 4.3 vs. 4 mo, p = 0.002). Concurrent bone and extraosseous metastases were associated with worse prognosis compared with each site alone (median OS: 12.3 vs.19 vs.18.3 mo, p = 0.007). Conclusions: Among patients with AIPC treated with biweekly docetaxel and estramustine, baseline PSA &amp;gt;100, existence of pain, weight loss, and simultaneous extraosseous and bone disease were associated with worse prognosis. Extraosseous metastases seem to be more sensitive than bone disease to this chemotherapy. © 2007 European Association of Urology.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><notes><style face="normal" font="default" size="100%">Cited By :18Export Date: 21 February 2017</style></notes></record></records></xml>